Nine months ago, I stepped on my doctor's scale and heard words I'd been working toward for two years: "You've lost 61 pounds. This is remarkable."
My A1C was down. My blood pressure was normal for the first time in a decade. I cried in the parking lot — happy tears, the kind I hadn't felt in a long time.
Three weeks later, I got a different kind of news.
My daughter had pushed me to get a DEXA scan. She'd read something about it online. I didn't think much of it — I figured it would confirm how well things were going.
A DEXA scan measures body composition in detail: not just total weight, but the specific ratio of fat to lean muscle mass to bone density. It's the kind of data a standard weigh-in simply cannot provide.
What it showed stopped me cold.
Out of 61 pounds, 22 pounds was muscle. Not fat. Muscle.
And nobody — not my prescribing doctor, not my internist, nobody — had mentioned that this could happen.
My experience, I later learned, is not unusual. Research published in the past two years on GLP-1 medications — semaglutide and tirzepatide — consistently shows that a meaningful share of weight lost on these medications may come from lean muscle mass, not fat tissue.*
For adults over 50, who are already experiencing natural age-related muscle changes, this can have real consequences that do not show up on a scale: fatigue, reduced strength, changes in mobility, and — as I discovered — shifts in bone density.
"I felt it before I saw the scan," I told a friend. "I was losing weight and should have felt energized. But I was exhausted. I needed the railing on the stairs. I kept thinking I was just adjusting to the medication."
The scale said I was winning. My body was telling me something different. I just did not have the vocabulary for what was happening yet.
After the scan, I started researching. I found a growing body of literature — from sports science and clinical nutrition — pointing to one intervention with substantial published evidence for supporting lean mass during caloric deficit: creatine monohydrate.*
"I was not looking for a miracle," I wrote in my journal at the time. "I was looking for something with actual research behind it, something that would not interact with my medication, and something I could realistically take every single day." That last part matters more than people think when you are already managing nausea and food aversion.
I tried creatine powder first. Two weeks in, I stopped. The measuring, the mixing — when you already feel queasy, adding a chalky drink to your morning is not a habit that lasts.
The format that finally worked was one I had not expected: gummies.
Specifically, I found PRESERVE™ — a creatine monohydrate gummy developed for adults 50+ on GLP-1 therapy. Each gummy contains 1,250mg of creatine monohydrate. Four gummies equals the full 5g research-established daily dose, taken in the morning with water — or in my case, with my first cup of coffee.
The first creatine gummy developed specifically for adults 50+ on GLP-1 therapy. Research-dosed. Third-party tested. Sugar-free. Four gummies a day — no measuring, no mixing, no compromise.
3,400+ adults 50+ are already on the protocol. Q2 batch shipping now. 60-day risk-free.
Start the Protocol — From $54256-bit SSL · No surprise charges · Cancel anytime in your account
Disclosure: This is a personal story shared with and sponsored by PRESERVE™ Daily. Susan K. received compensation. Individual results vary and are not guaranteed. Susan's DEXA results are her personal experience and may not be representative of typical outcomes.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement, especially if you take prescription medications or have existing health conditions.
PRESERVE™ does not contain GLP-1 or any GLP-1 receptor agonist. PRESERVE™ is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S or Eli Lilly and Co. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. References to these medications are informational only.
Research references: Multiple peer-reviewed analyses of GLP-1 medications and body composition outcomes (2023-2025) · DEXA scan methodology and age-related muscle research · 500+ peer-reviewed studies on creatine monohydrate safety and efficacy.